Publications by authors named "R A Ghossein"

Aims: Although molecular tests developed for a growing list of oncogenic alterations have significantly aided in the classification of head and neck carcinomas, tumours in which prototypical histologic and immunophenotypic features are lacking or only partially developed continue to pose diagnostic challenges. Searching for known diagnostic and therapeutic targets by clinical next-generation sequencing (NGS) assays can often lead to new discoveries.

Methods And Results: We present our institutional experience in applying targeted RNA NGS in 36 head and neck carcinomas that were morphologically difficult to classify between 2016 and 2023.

View Article and Find Full Text PDF

The diagnosis and treatment of sinonasal small round epithelial/neuroepithelial malignancies depend on the expression of conventional neuroendocrine markers (NEMs), such as synaptophysin, chromogranin A, INSM1, and CD56/NCAM1. However, these tumors remain diagnostically challenging because of overlapping histologic and immunohistochemical features. The transcriptional regulators ASCL1, NEUROD1, POU2F3, and YAP1 are novel NEM (nNEM) used for the subtyping of small-cell lung cancer (SCLC).

View Article and Find Full Text PDF

Purpose: BSND is a chloride channel subunit that is expressed in the normal salivary gland. We aimed to validate the utility of BSND immunohistochemistry in the differential diagnosis of oncocytic salivary gland neoplasms.

Methods: BSND immunohistochemistry was performed in a retrospective cohort of 93 salivary gland lesions, enriched with tumors with oncocytic features and histologic variants of mucoepidermoid carcinoma (MEC).

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the effectiveness of Fluorine 18-labelled tetrafluoroborate ([F]TFB) as an imaging alternative to iodine for assessing metastatic thyroid cancer and potential radioiodine treatment success.
  • Five patients participated in the research, receiving both [F]TFB and iodine imaging on the same day. Results showed that [F]TFB identified 58% of lesions compared to 91% for iodine imaging, indicating its lower sensitivity.
  • The conclusion drawn highlights that [F]TFB did not successfully predict iodine uptake in patients undergoing redifferentiation therapy, raising questions about its reliability for other treatment cases or in untreated patients.
View Article and Find Full Text PDF
Article Synopsis
  • Seizure-related 6 homolog (SEZ6) is linked to neuroendocrine differentiation and has been found to be highly expressed in medullary thyroid carcinoma (MTC), as well as small cell lung carcinoma (SCLC).
  • A novel antibody drug, ABBV-011, targeting SEZ6 is currently in clinical trials for treating SCLC and neuroendocrine neoplasms, suggesting potential therapeutic applications.
  • SEZ6 shows high immunoexpression in a majority of MTC cases, making it a promising biomarker, even though it does not correlate with patient outcomes or certain mutations, highlighting its potential for targeted therapy.
View Article and Find Full Text PDF